Evogene Ltd.

Evogene Ltd. is an Israeli computational chemistry company that specializes in the generative design of small molecules for the pharmaceutical and agricultural industries. Headquartered in Rehovot, Israel, the company's mission is to revolutionize product development in life sciences by leveraging its proprietary Computational Predictive Biology (CPB) platform and its core generative AI engine, ChemPass AI™.

At the heart of Evogene's offerings is ChemPass AI™, which is designed to create novel, highly potent small molecules optimized across multiple critical parameters, thereby improving success rates and reducing development time and costs. The company applies this technology across various market segments, including human health for drug discovery and agriculture for the development of ag-chemicals. While Evogene previously advanced product pipelines through subsidiaries in areas such as human microbiome-based therapeutics (Biomica), medical cannabis (Canonic), ag-biologicals (Lavie Bio), and castor oil production (Casterra), it has recently undergone a strategic refocus.

In 2025, Evogene initiated a strategic transformation to concentrate on its ChemPass AI™ platform, divesting non-core assets such as Lavie Bio and licensing Biomica's lead oncology candidate. The company has expanded its collaboration with Google Cloud to integrate advanced AI agents into ChemPass AI™ to accelerate small-molecule discovery. Ofer Haviv serves as the President and CEO, guiding the company's efforts to translate generative AI discoveries into commercially viable products through strategic partnerships and internal expertise.